Left Atrial Appendage Occlusion vs Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: A Meta‐Analysis
Key result
LAAO matches oral anticoagulation for MACE while significantly reducing non-procedural bleeding.
- RR 1.03
- 95% CI 0.79-1.34
- n=7,004
Why the study?
An updated synthesis of evidence is warranted to clarify the long-term comparative efficacy and safety of left atrial appendage occlusion versus oral anticoagulation in patients with atrial fibrillation following recent trials.
Does left atrial appendage occlusion improve clinical outcomes (MACE, stroke) and prevent bleeding compared to oral anticoagulation in adults with atrial fibrillation?
Key Points
- To evaluate the comparative long-term efficacy and safety of left atrial appendage occlusion versus oral anticoagulation for stroke prevention in patients with atrial fibrillation.
- Systematic review and meta-analysis of 6 randomized controlled trials (N=7,004; 3,681 receiving left atrial appendage occlusion and 3,323 receiving oral anticoagulation) identified from database inception to April 2026.
- Synthesized primary efficacy outcomes (major adverse cardiovascular events and stroke) and primary safety outcome (non-procedure-related bleeding) using random-effects models and trial sequential analysis.
- Left atrial appendage occlusion significantly lowered non-procedure-related bleeding compared with oral anticoagulation (9.8% vs 16.7%; RR 0.63, 95% CI 0.52–0.77; absolute risk reduction 6.9%).
- No statistically significant difference occurred between left atrial appendage occlusion and oral anticoagulation for major adverse cardiovascular events (7.5% vs 6.9%; RR 1.03, 95% CI 0.79–1.34) or stroke (3.7% vs 3.2%; RR 1.07, 95% CI 0.80–1.43).
- Trial sequential analysis showed that evidence for major adverse cardiovascular events and stroke remains inconclusive, with no significant interaction between direct oral anticoagulant and vitamin K antagonist trials (p=0.67 for MACE; p=0.81 for stroke).
Study Design
Type
Meta-Analysis (n=7,004)
Structured PICO
Does left atrial appendage occlusion improve clinical outcomes (MACE, stroke) and prevent bleeding compared to oral anticoagulation in adults with atrial fibrillation?
P
Population
7,004 adults with atrial fibrillation pooled from 6 randomized controlled trials comparing left atrial appendage occlusion to oral anticoagulation.
I
Intervention
Left atrial appendage occlusion (LAAO)
C
Comparator
Oral anticoagulation (OAC), including direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs)
O
Outcome
Major adverse cardiovascular events (MACE) and stroke (primary efficacy outcomes); non-procedure-related bleeding (primary safety outcome)composite
Main Result
Relative Risk: 1.03 (95% CI 0.79–1.34)
Absolute Event Rate: 7.5% vs 6.9%
Limitations
- Efficacy evidence remains inconclusive regarding equivalence or non-inferiority
- Larger trials are needed
- accumulated evidence for efficacy (MACE and stroke) remains inconclusive regarding equivalence or non-inferiority
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“I see the data as strengthening the case against using LAAC as a substitute for oral anticoagulation. There is a clear signal of higher rates of ischemic stroke. From a Bayesian point of view, the probability of reaching non-inferiority for stroke and systemic embolism using a lax measure of 1.4 is less than 50%.”
AGAndrew GoldsweigCardiologist, University of Massachusetts-Baystate
“While the present analysis is congruent to other recent meta-analyses in identifying slightly higher ischemic stroke and lower nonprocedural bleeding rates, Rai et al suggest the novel findings that all-cause stroke may be higher with LAAO (70% chance) but that major bleeding may be lower with LAAO (86% chance)”
ARAmar RaiResearcher, University of Pennsylvania / Imperial College London
“The reason we did this is mainly [to see if this could] be an effective alternative to long-term anticoagulation in patients. And when you go back to that, it is useful, but we don't know what population group yet.”
Implication
In patients with atrial fibrillation, left atrial appendage occlusion reduces the risk of non-procedure-related bleeding compared to oral anticoagulation, though current evidence remains inconclusive to establish definitive non-inferiority for stroke and MACE prevention.
Abstract
BACKGROUND: Left atrial appendage occlusion (LAAO) has emerged as a non-pharmacological alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation (AF). Following the publication of recent CHAMPION-AF and CLOSURE-AF trials, an updated synthesis of evidence is warranted to clarify the long-term comparative efficacy and safety of LAAO versus OAC in patients with AF. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing LAAO with OAC in adults with AF. A comprehensive search of major databases was performed from inception to April 2026. The primary efficacy outcomes were major adverse cardiovascular events (MACE) and stroke. The primary safety outcome was non-procedure-related bleeding. Random-effects models were used to calculate pooled risk ratios (RRs) with 95% confidence intervals (CIs). RESULTS: Six RCTs including 7,004 patients (3,681 LAAO; 3,323 OAC) were analyzed. No statistically significant difference was observed for MACE (7.5% vs 6.9%; RR 1.03, 95% CI 0.79-1.34) or stroke (3.7% vs 3.2%; RR 1.07, 95% CI 0.80-1.43). LAAO was associated with a significantly lower risk of non-procedure-related bleeding (9.8% vs 16.7%; RR 0.63, 95% CI 0.52-0.77), corresponding to an absolute risk reduction of 6.9% and an approximate number needed to treat of 15 based on crude pooled event rates over the observed trial follow-up. Trial sequential analysis indicated that the accumulated evidence for MACE and stroke remained inconclusive. Comparator-type subgroup analyses showed no significant interaction for MACE (p = 0.67) or stroke (p = 0.81) between contemporary predominantly-DOAC and VKA comparator trials. CONCLUSIONS: LAAO was associated with lower non-procedure-related bleeding, while no statistically significant differences were observed for MACE or stroke. The available efficacy evidence remains inconclusive regarding equivalence or non-inferiority, and larger trials are needed. These findings support individualized consideration of LAAO when the long-term bleeding burden of anticoagulation is clinically important.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Nazmy et al. (2026) conducted a meta-analysis in Atrial fibrillation (n=7,004). Left atrial appendage occlusion (LAAO) vs. Oral anticoagulation (OAC) was evaluated on Major adverse cardiovascular events (MACE) (RR 1.03, 95% CI 0.79-1.34). Left atrial appendage occlusion yielded no significant difference in MACE (RR 1.03; 95% CI 0.79-1.34) versus oral anticoagulation, but significantly reduced non-procedure-related bleeding.